Evidence map›Paper›PMID 29761102›Full record

ArticleFrontiers in medicine2018

Reactivation of a Vaccine Escape Hepatitis B Virus Mutant in a Cambodian Patient During Anti-Hepatitis C Virus Therapy.

Dahlene N Fusco, Lilia Ganova-Raeva, Yury Khudyakov, Lili Punkova, Aisha Mohamed, Scarlett Se Yun Cheon, Prapti Koirala, Karin L Andersson, Gonzague Jourdain, Camille Sureau and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dahlene N FuscoMedicine/General Internal Medicine and Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Lilia Ganova-RaevaMolecular Epidemiology and Bioinformatics Team, DVH/NCHHSTP/CDC, Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States.
Yury KhudyakovMolecular Epidemiology and Bioinformatics Team, DVH/NCHHSTP/CDC, Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States.
Lili PunkovaMolecular Epidemiology and Bioinformatics Team, DVH/NCHHSTP/CDC, Centers for Disease Control and Prevention (CDC), Atlanta, GA, United States.
Aisha MohamedCooper Medical School of Rowan University, Camden, NJ, United States.
Scarlett Se Yun CheonWellesley College, Wellesley, MA, United States.
Prapti KoiralaWellesley College, Wellesley, MA, United States.
Karin L AnderssonGastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Gonzague JourdainInstitut de recherche pour le développement(IRD), Marseille, France.
Camille SureauInstitut National de la Tranfusion Sanguine INSER U1134, Paris, France.
Raymond T ChungGastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.
Georg LauerGastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.

Funding

TRANSLATIONAL PHARMACOLOGY COREP50GM107618 · NIGMS · HARVARD MEDICAL SCHOOL · PI GOLAN, DAVID E. · 2014 to 2018
$10.8M
Interferon Effector Gene Activation to Circumvent Viral ImpedanceK08AI108629 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI FUSCO, DAHLENE NICOLE · 2014 to 2016
$559k
NIAID NIH HHS K08 AI108629NIGMS NIH HHS P50 GM107618
6 · The paper itself

Abstract

A 76-year-old Cambodian man co-infected with hepatitis B virus (HBV) and hepatitis C virus (HCV) 6c-1 presented for care. HBV DNA was intermittently detectable despite anti-HBs levels being above the protective threshold. During treatment for HCV, HBV DNA levels increased. Sequencing revealed multiple mutations including vaccine escape mutation and mutations predicted to enhance fitness. This case represents exacerbation of an HBV vaccine escape mutant during a direct-acting antiviral therapy.

Indexed as

HBV vaccine escape mutantHCVhepatitis B viruspreS2 deletionsurface antibody escape mutant

Identifiers

PMID29761102
PMCPMC5936758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.